Company intelligence / Profile preview
Obecure Ltd.
Ramat Gan, Israel
- Ownership
- Private
- Development stage
- Other
01
Overview
Obecure developed Histalean™ (betahistine hydrochloride), which showed positive results in a Phase Ib proof-of-concept study for mitigating weight gain associated with the antipsychotic drug Olanzapine. The company also had OBE101 in Phase II trials for weight loss and OBE-102 for obesity, but development appears to have been discontinued[1][3][4].
- Therapeutic areas
- EndocrinologyPsychiatry
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Obecure Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Obecure Ltd..